IDEANOMICS, INC.: Nasdaq/NYSE listing notice — Ideanomics receives Nasdaq notice for audit committee non-compliance; cure period through Oct 2023

IDEANOMICS, INC.

Nasdaq notified Ideanomics on Nov 30, 2022 that its Audit Committee has only 2 independent directors, violating Listing Rule 5605.
Cure period ends at earlier of next annual meeting or Oct 31, 2023; if meeting before May 1, 2023, then by May 1, 2023.
Company plans to appoint an additional independent director to the Board and Audit Committee as soon as practicable.
The deficiency has no immediate effect on listing or trading of IDEX common stock on the Nasdaq Capital Market.
There is no assurance the Company will regain compliance or maintain other listing requirements.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

IDEANOMICS, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605

Exact text from the filing

November 30, 2022, Ideanomics, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was no longer in compliance with the audit committee requirements as set forth in Nasdaq Listing Rule 5605, which requires the Audit Committee of the Board of Directors of the Company (the “Audit Committee”) to be comprised of a minimum of three independent directors. The Audit Committee is currently comprised of two independent directors and one vacancy. The Letter provides that the Company is eligible for a cure period in which to regain

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-22-124087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.